The PAX3-FOXO1 fusion gene is generated by a 2;13 chromosomal translocation and is a characteristic feature of an aggressive subset of rhabdomyosarcoma (RMS) 
Introduction
Rhabdomyosarcoma (RMS) is a common paediatric soft tissue tumour that is associated with the skeletal muscle lineage. RMS comprises two major histopathological subtypes: alveolar RMS (ARMS) and embryonal RMS. ARMS is the more aggressive subtype, and is characterized by a t(2;13)(q35; q14) or t(1;13)(p36; q14) chromosomal translocation, which generates a PAX3-FOXO1 or PAX7-FOXO1 fusion gene [1] [2] [3] [4] . These fusion genes combine functional domains from the corresponding wild-type proteins to produce novel chimaeric transcription factors with increased activation of PAX3/PAX7 target genes and associated oncogenic function [5] [6] [7] [8] .
Earlier studies identified the myoblast as a potential cell of origin for RMS. Ectopic expression of PAX3-FOXO1 in primary human skeletal muscle myoblasts confers a proliferative advantage by bypassing cellular senescence; this bypass is associated with loss of CDKN2A expression [9] . PAX3-FOXO1 alone is not sufficient for tumourigenesis but requires additional changes, such as increased MYCN and TERT expression [10, 11] . In our previous study of immortalized human myoblasts, PAX3-FOXO1 alone did not transform myoblasts in culture, and induced slow-growing tumours in immunocompromised mice.
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In contrast, the combination of PAX3-FOXO1 and MYCN transformed the myoblasts and induced rapid tumourigenesis [12] .
An important limitation of studies with constitutive PAX3-FOXO1 expression is that expression cannot be manipulated to analyse the temporal and quantitative requirements for PAX3-FOXO1. To overcome this limitation, we developed a doxycycline-inducible PAX3-FOXO1 expression system in immortalized human myoblasts. With this system, expression of PAX3-FOXO1 and its downstream targets can be regulated by doxycycline addition or withdrawal to study the requirements for PAX3-FOXO1. We provide evidence that PAX3-FOXO1 in combination with MYCN contributes to myoblast transformation and tumour formation by stimulating proliferation and inhibiting myogenic differentiation and apoptosis. After tumour formation, cessation of PAX3-FOXO1 expression results in tumour regression. Following regression, recurrent tumours eventually form in which PAX3-FOXO1 is not required to maintain the tumourigenic phenotype. These studies further our understanding of PAX3-FOXO1 function in ARMS tumourigenesis and recurrence, and provide an important model with which to investigate the effects of therapies directed against the fusion protein.
Materials and methods
Cell culture
An immortalized human Duchenne muscular dystrophy myoblast cell line (Dbt) and human RMS cell lines were cultured as described previously [12] . Verification of cell line identity was performed by short tandem repeat genotyping analysis with the AmpFLSTR profiler plus polymerase chain reaction (PCR) amplification kit (Applied Biosystems, Foster city, CA, USA).
Lentiviral transduction
The PAX3-FOXO1 fusion cDNA was subcloned into the lentiviral doxycycline-inducible pINDUCER10 vector (provided by J. Luo). A single-guide RNA (sgRNA) targeting the 5 ′ PAX3 region was designed (supplementary material, Table S1 ) and cloned into the lentiCRISPR v2 plasmid (provided by J. Luo) [13] [14] [15] . Oligonucleotides were purchased from Integrated DNA Technologies, Coralville, IA, USA. Lentiviral particles were prepared in HEK293T cells with the human immunodeficiency virus-based pPACK-H1 Packaging Plasmid Mix (System Biosciences, Mountain View, CA, USA).
Establishment of stable cell lines
Dbt cells were transduced with the empty retroviral pK1 vector or a MYCN-expressing construct, and selected in hygromycin (120 μg/ml) as described previously [12] . These cells were further transduced with pINDUCER10 containing firefly luciferase or PAX3-FOXO1, and selected with puromycin (1.5 μg/ml) to prepare Dbt-indP3F and Dbt-MYCN/indP3F parental cell populations, respectively ('parental' is specifically used to refer to these starting transduced populations). Subclones were isolated from parental populations by limiting dilution. Engineered Dbt cells were incubated with doxycycline (Sigma-Aldrich, St. Louis, MO, USA) to induce PAX3-FOXO1 expression. In some cases, engineered Dbt cells were further transduced with a green fluorescent protein (GFP) expression construct (Addgene plasmid no. 17445) [16] .
Expression assays
Western blotting of cell and tumour lysates was performed as described previously [17] , with antibodies against FOXO1 (1:1000, no. 2880; Cell Signaling Technology, Danvers, MA, USA) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:1000, no. sc-25778; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Total RNA was extracted, and quantitative reverse transcription PCR (qRT-PCR) was performed as described previously [17] . Taqman gene expression assays (Life Technologies, Carlsbad, CA, USA) were used to quantify PAX3-FOXO1 (Hs03024825), MYCN (Hs00232074) and GAPDH (Hs02758991) under standard cycling conditions. To specifically measure endogenous MYCN expression, a qRT-PCR assay was developed for the MYCN 3 ′ -untranslated region (UTR) (supplementary material, Table S1 ). The ΔΔC t method was used to assess the gene expression fold change.
Oncogenicity assays
Oncogenic transformation was measured with focus formation assays as described previously [18] . Engineered Dbt myoblasts (10 6 cells) were injected into the left gastrocnemius muscle of 4-week-old female NOD-SCID mice (Frederick National Laboratory for Cancer Research, Frederick, MD, USA). Mice were fed either a regular or doxycycline-containing (625 mg/kg) diet (Harlan Laboratories, Indianapolis, IN, USA), beginning 3 days prior to injection; the feed was replenished twice weekly. The mice were observed for tumour formation for 90 days. Tumour volume was calculated according to the formula (length × width 2 /2), where length represents the largest tumour diameter and width represents the perpendicular tumour diameter. Cell lines were derived from xenograft tumours as described previously [12] , and injected into mice as described above. All experimental procedures were approved by the NIH Animal Care and Use Committee.
Immunohistochemistry (IHC)
Tissue sections from tumour specimens were immunostained as described previously [19] . Primary rabbit and mouse antibodies were applied at the following dilutions: PAX3-FOXO1 fusion-specific antibody [20] 
Results
Doxycycline-inducible PAX3-FOXO1 expression system
To investigate the role of PAX3-FOXO1 in RMS tumourigenesis, we transduced immortalized human myoblasts with doxycycline-inducible PAX3-FOXO1 and constitutive MYCN expression constructs to prepare mixed transduced cell populations. In a time-course experiment, PAX3-FOXO1 mRNA and protein were expressed by 24 h following doxycycline treatment in Dbt-indP3F cells (containing inducible PAX3-FOXO1 alone) and Dbt-MYCN/indP3F cells (containing constitutive MYCN and inducible PAX3-FOXO1) ( Figure 1A ). Doxycycline treatment resulted in a dose-dependent increase in expression of PAX3-FOXO1 ( Figure 1B ; supplementary material, Figure S1A ) and of FGFR4, a downstream target of PAX3-FOXO1 (supplementary material, Figure S1B ). In contrast, there was constitutive high MYCN expression in Dbt-MYCN/indP3F cells, and no detectable MYCN expression in Dbt-indP3F cells ( Figure 1B ) (supplementary material, Figure S1C ). In a qRT-PCR assay specific for the MYCN 3 ′ -UTR, there was no evidence of endogenous MYCN expression induced by PAX3-FOXO1 in these cells (supplementary material, Figure S1D ).
We next investigated the effects of doxycycline withdrawal, to determine the reversibility of this inducible system. Engineered Dbt cells were cultured for 48 h in the presence of doxycycline, and then replenished with fresh medium lacking doxycycline. PAX3-FOXO1 mRNA and protein expression decreased to almost undetectable levels as early as 24 h following doxycycline removal ( Figure 1C ; supplementary material, Figure S1E ). Therefore, this doxycycline-inducible PAX3-FOXO1 system in human myoblasts provides reversible, quantitative and reproducible control of PAX3-FOXO1 expression to study the oncogenic effects of this fusion protein. The effect of PAX3-FOXO1 depletion in Dbt-MYCN/indP3F cells (also transduced with GFP) was evaluated in the focus formation assay by withdrawing doxycycline at day 9 from one group of plates (+/-), and another group was continuously treated with doxycycline (+/+). Representative images are shown of fluorescence microscopy on day 9 and day 17, as well as of whole plates fixed and stained on day 9 and day 17. Scale bar: 400 μm. Dox, doxycycline.
Effects of PAX3-FOXO1 on oncogenic transformation
To explore the phenotypic role of PAX3-FOXO1 alone or in combination with MYCN, we assessed oncogenic transformation with focus formation assays. Dbt cells containing the empty vector (Dbt-control), MYCN alone (Dbt-MYCN) or PAX3-FOXO1 alone did not form foci in the absence or presence of doxycycline ( Figure 2A ). In contrast, Dbt-MYCN/indP3F cells were transformed in the presence of doxycycline. These results corroborated previous findings that multiple genetic changes are required to transform human cells [10, 11] .
We then analysed the requirement for continued PAX3-FOXO1 expression in transformed foci arising in the focus formation assay. We initially performed the assay with Dbt-MYCN/indP3F cells in the presence of doxycycline, as described above. After small foci appeared at day 9, doxycycline treatment was discontinued in half of the plates. In plates with continued doxycycline treatment, foci continued to grow during the following 8 days ( Figure 2B ). Microscopy revealed that these large foci contained tightly packed small undifferentiated cells. In contrast, in plates in which doxycycline treatment was discontinued for 8 days, foci were smaller and showed prominent myotube formation consistent with myogenic differentiation. In other areas, there was bleb formation and cell swelling indicative of cell injury and death. These results indicate that PAX3-FOXO1 inhibits myogenic differentiation and cell death, and maintains cells in the proliferative state to exert transforming effects.
Effect of PAX3-FOXO1 on tumour formation
To assess the oncogenic role of PAX3-FOXO1 in vivo and determine whether MYCN modifies this phenotype, we performed intramuscular injections of the mixed Dbt-control, Dbt-MYCN, Dbt-indP3F and Dbt-MYCN/indP3F parental cells in NOD-SCID mice fed a standard or doxycycline-supplemented diet. We observed that only Dbt-indP3F and Dbt-MYCN/indP3F Table S2 ). The combination of constitutive MYCN and inducible PAX3-FOXO1 expression resulted in rapid tumour formation (4-5 weeks) in all mice ( Figure 3A ). In contrast, PAX3-FOXO1 expression alone caused tumours after a much longer latency period (9-10 weeks). qRT-PCR, western blot and IHC assays confirmed that doxycycline induced high PAX3-FOXO1 expression in tumour cells (Figure 3B , C; supplementary material, Figure S2A , B). The IHC assay identified a heterogeneous PAX3-FOXO1 expression pattern, which may be attributable to cell cycle differences, microenvironmental effects, or clonality heterogeneity. In addition, western blot and qRT-PCR studies revealed endogenous MYCN mRNA and protein in these tumours ( Figure 3C ; supplementary material, Figure S2A ), in contrast to the findings described above in parental cell lines.
Microscopic examination of haematoxylin and eosin (H&E)-stained slides revealed that tumours derived from Dbt-indP3F and Dbt-MYCN/indP3F myoblasts showed a similar histological pattern, resembling human ARMS ( Figure 3B ; supplementary material, Figure S2B ). In particular, the tumours consisted of a dense and often sheet-like population of small to medium round cells. Tumour giant cells were present in varying numbers, and were particularly frequent in tumours formed from Dbt-indP3F cells (supplementary material, Figure S2B ).
To further characterize these tumours, IHC was performed to detect proliferative and myogenic markers ( Figure 3B ; supplementary material, Figure S2B ). Staining for Ki67 demonstrated strong and diffuse reactivity, confirming the presence of a high proliferative rate in tumour cells. Most tumour cells also stained for the myogenic marker myogenin, consistent with the diagnosis of RMS. These IHC findings were similar in tumours expressing PAX3-FOXO1 with or without MYCN. 
Tumour regression following PAX3-FOXO1 depletion
We next investigated whether continuous PAX3-FOXO1 expression was required in the later stages of tumourigenesis by downregulating PAX3-FOXO1 expression in these tumours. In particular, mice were switched to a standard diet without doxycycline supplementation after palpable tumours formed ( Figure 4A ; supplementary material, Figure S3A , B). Shortly after discontinuation of doxycycline, all tumours formed from Dbt-indP3F or Dbt-MYCN/indP3F cells regressed, became undetectable within 1 week, and remained in this state during the next 3 weeks of observation.
The events occurring during tumour regression were examined in a time-course experiment in which tumours were harvested 0, 3, 6 and 9 days after doxycycline withdrawal. qRT-PCR, western blot and IHC assays revealed that PAX3-FOXO1 mRNA and protein expression decreased to nearly undetectable levels by 3 days after doxycycline withdrawal, and remained at this level to day 9 (Figure 4B, C; supplementary material, Figure S3C, D) . This observation confirms that high Microscopic examination of the regressing lesions further elucidated the pathways involved in maintaining the tumourigenic phenotype. By 3 days following doxycycline withdrawal, cell proliferation, as assessed by Ki67 expression, was almost completely shut down ( Figure 4B; supplementary material, Figure S3D ). In addition, there was widespread formation of multinucleated giant cells expressing high levels of myogenin, indicative of cell fusion and myogenic differentiation. In addition, many cells showed hyperchromasia and cleaved caspase-3 expression, consistent with superimposed cell death. Therefore, as found in our in vitro assays, PAX3-FOXO1 is needed in vivo to stimulate proliferation and inhibit differentiation and cell death of tumour cells. By 9 days after doxycycline withdrawal, the giant cells were very prominent, both in number and size, consistent with continued differentiation. Expression of cleaved caspase-3 decreased and hyperchromasia was no longer detectable, indicating that a wave of cell death was ending. Furthermore, there was increased Ki67 expression in mononuclear tumour cells, indicating restored proliferation of cells that did not undergo differentiation or cell death. These findings suggest that a subpopulation of proliferative cells is able to recover after loss of PAX3-FOXO1 expression.
Recurrence of myoblast-derived tumours
Although regressed tumours from Dbt-MYCN/indP3F myoblasts were undetectable for 3 weeks following doxycycline withdrawal, tumour cells eventually grew in the absence of doxycycline and formed recurrent tumours ( Figure 4A ; this recurrence phenomenon was not studied in tumours derived from Dbt-indP3F cells, because of the late occurrence of the primary tumours). Microscopic analysis showed that the recurrent tumours consisted of one or more prominent nodules or multiple smaller foci containing densely packed small round cells ( Figure 4B ; supplementary material, Figure  S3D ). Surrounding these nodules and foci, there were extensively differentiated areas consisting of numerous giant cells and myotubes. The proliferative status of the nodules and foci was demonstrated by high Ki67 levels, which contrasted with the relatively low expression in surrounding differentiated cells. Cells in the proliferating areas also stained with myogenin, confirming the myogenic nature of the recurrences. Myogenin was also expressed in differentiated areas but appeared less prominent.
We next assessed PAX3-FOXO1 expression in these recurrent tumours. Sixty per cent of recurrences showed no detectable PAX3-FOXO1 expression by IHC and western blotting (Figure 4B, D; supplementary material, Figure S3D ), consistent with a PAX3-FOXO1-independent recurrence mechanism. In another subset of recurrent tumours, PAX3-FOXO1 was expressed in the absence of doxycycline ( Figure 4D) ; these latter changes are considered to be experimental artefacts that uncouple PAX3-FOXO1 from the doxycycline-inducible system.
Characterization of tumour-derived cell lines
Cell lines were generated from primary and recurrent tumours arising in these experiments. Western blotting showed that all examined primary and recurrent tumour-derived cell lines only expressed PAX3-FOXO1 protein in the presence of doxycycline, except for one recurrent tumour-derived line that expressed PAX3-FOXO1 with or without doxycycline ( Figure 5A ). The expression findings in the tumour-derived lines are in agreement with findings in the corresponding tumours, except for most recurrent tumours expressing PAX3-FOXO1 in the absence of doxycycline. The discordance in PAX3-FOXO1 expression without doxycycline between these recurrent tumours and associated cell lines suggests that the mechanism for doxycycline-independent PAX3-FOXO1 expression in these tumours reflects environmental specificity or cell line-independent heterogeneity. MYCN expression in these tumour-derived lines resembled that in the corresponding parental lines. In particular, the increased endogenous MYCN expression found in tumours was not maintained in the tumour-derived lines (supplementary material, Figure  S4A ), suggesting that MYCN is only induced in vivo by PAX3-FOXO1 in this experimental system.
The transformation potential of these tumour-derived cell lines was assessed with focus formation assays. All primary tumour-derived lines were transformed in the presence of PAX3-FOXO1 induction ( Figure 5B ). It is of note that tumour-derived cells expressing PAX3-FOXO1 alone formed foci, whereas the parental Dbt-indP3F myoblasts did not. This discordance may be explained by in vivo selection of transformed clones with additional molecular changes during tumour formation and/or changes caused by the tumour microenvironment. All lines derived from recurrent tumours were also transformed in the presence of doxycycline, indicating that the fusion protein is still functional when induced. In addition, most lines derived from recurrent tumours that did not express PAX3-FOXO1 formed foci in the absence of PAX3-FOXO1 induction, supporting the premise that many recurrent tumours develop a PAX3-FOXO1-independent mechanism of transformation and tumourigenesis.
To provide further evidence that many recurrent tumours do not require PAX3-FOXO1 expression, we used the CRISPR/Cas9 system to knock down PAX3-FOXO1 in Dbt-MYCN/indP3F parental cells and representative recurrent tumour-derived cells. Following transduction of a CRISPR construct targeting the 5 ′ PAX3 region, PAX3-FOXO1 protein expression was knocked down to nearly undetectable levels in all of these lines in the presence of doxycycline (supplementary material, Figure S4B ). In oncogenicity assays, parental cells transduced with the 5 ′ PAX3-specific CRISPR construct failed to form foci when treated with 5 /6-cm dish) were cultured in medium consisting of 50% F-10 and 50% Dulbecco's modified Eagle's medium. Medium and doxycycline (500 ng/ml) were replenished every 2-3 days and incubated for up to 6 days. Scale bar: 400 μm. Dox, doxycycline; KO, knockout.
doxycycline, whereas control transduced cells formed numerous foci, as expected ( Figure 5C ). In contrast, the PAX3-specific CRISPR did not affect the ability of the postulated PAX3-FOXO1-independent recurrent tumour-derived lines to form foci in the absence or presence of doxycycline, confirming that the oncogenicity of these cells does not require fusion protein expression. However, in a recurrent tumour-derived line expressing PAX3-FOXO1 in a doxycycline-independent fashion, transforming activity (with or without doxycycline) was abolished by the PAX3-specific CRISPR construct, indicating that PAX3-FOXO1 expression is essential for transformation in this second category of recurrent tumours.
There was also a striking distinction in differentiation status between primary and recurrent tumour-derived cells. In standard growth-promoting medium, Dbt-indP3F, Dbt-MYCN and Dbt-MYCN/indP3F parental cells proliferated without any differentiation in the absence or presence of doxycycline. In contrast, cells derived from primary tumours expressing PAX3-FOXO1 with or without MYCN showed morphological evidence of differentiation when PAX3-FOXO1 expression was turned off by doxycycline withdrawal (Figure 5D ). In the presence of doxycycline (and thus PAX3-FOXO1 expression), the primary tumour-derived cells proliferated with significantly less or no differentiation, confirming the necessity of PAX3-FOXO1 for inhibiting differentiation and maintaining the proliferative phenotype. Furthermore, recurrent tumour-derived cells did not differentiate in the absence or presence of PAX3-FOXO1 induction, indicating that these cells developed a PAX3-FOXO1-independent differentiation block as part of the recurrence process. Similar findings were noted in focus formation assays in which doxycycline treatment was either discontinued or maintained after small foci formed (supplementary material, Figure  S4C ). In the continued presence of doxycycline, foci formed from all primary and recurrent tumour-derived lines were composed of tightly packed small round undifferentiated cells. However, when doxycycline was withdrawn after small foci formed, there was widespread differentiation in foci formed from primary tumour-derived cells, but no differentiation was evident in foci formed from recurrent tumour-derived cells, corroborating the PAX3-FOXO1-independent differentiation block.
Tumourigenicity of tumour-derived cell lines
We finally compared in vivo tumourigenesis of the parental Dbt-indP3F and Dbt-MYCN/indP3F mixed populations with that of cell lines derived from primary and recurrent tumours. The primary tumour-derived cell lines from Dbt-indP3F myoblasts formed tumours more rapidly (3-4 weeks) than the parental Dbt-indP3F population (9-10 weeks) ( Figure 6A ). This finding further confirms the premise that tumourigenic cells with additional genetic changes were selected during tumourigenesis. In contrast, cells derived from primary tumours expressing MYCN and PAX3-FOXO1 formed PAX3-FOXO1 in rhabdomyosarcoma tumourigenesis 635 tumours at nearly the same rate as the parental population, indicating that many (and perhaps most) cells in the parental population have transforming and tumourigenic potential ( Figure 6B ). This premise was confirmed by studies of subclones prepared from the parental population; all three tested subclones showed relatively rapid tumour formation, with some heterogeneity in growth rates ( Figure 6C) .
The recurrent tumour-derived cells were also assayed for tumourigenesis with or without doxycycline. A recurrent tumour-derived line that did not express PAX3-FOXO1 and was transformed in the absence of doxycycline formed tumours rapidly in the absence of doxycycline. This finding corroborates a PAX3-FOXO1-independent mechanism of transformation and tumourigenesis ( Figure 6D ). It is of note that these cells formed tumours even more rapidly in the presence of doxycycline, suggesting that PAX3-FOXO1-dependent and PAX3-FOXO1-independent oncogenic mechanisms have additive effects that collaborate during tumourigenesis.
To further study the generality of these recurrence events, we compared recurrence rates in primary tumour-derived cells, parental Dbt-MYCN/indP3F cells, and subclones. We again withdrew doxycycline after palpable tumours were formed in the presence of doxycycline ( Figure 6E, F) . Except for one subclone (C12), there was a similar pattern of recurrence among all cell lines tested, indicating that recurrent tumours form from rare cells in the population after doxycycline withdrawal. It is of note that there was variation in the rate of recurrent tumour formation among the injected replicates of each cell line. For subclone C12, recurrent tumours arose at a uniformly high rate, suggesting that there is a pre-existing PAX3-FOXO1-independent tumourigenesis mechanism in this clonal population.
Discussion
In this study, we continued our longstanding investigations of the PAX3-FOXO1 oncoprotein in ARMS tumourigenesis. To study the dynamic and temporal relationship of this fusion oncoprotein with the tumourigenesis process, we developed a doxycycline-inducible PAX3-FOXO1 expression system in human myoblasts, which are postulated to be cells of origin of RMS. By inducing PAX3-FOXO1 in the presence or absence of constitutive MYCN expression, this system has validated previous findings of collaboration between PAX3-FOXO1 and MYCN in oncogenic transformation and tumourigenesis [12, 21] . Furthermore, this inducible expression system permitted us to dissect the role of PAX3-FOXO1 in initiating and maintaining the oncogenic phenotype. Our findings indicate that PAX3-FOXO1 induces transformation while inhibiting differentiation and cell death during the early phases of tumourigenesis. However, these phenotypes may be uncoupled from the fusion protein in later stages of tumour progression.
Our analysis is compatible with an initial phase of oncogene addiction during ARMS tumourigenesis. It is widely known that some tumours show exquisite dependence on a single oncogenic protein (or pathway) for sustaining growth and survival despite the presence of other mutations and aberrant pathways [22] . Such dependence has been demonstrated for oncogenic versions of MYC [23, 24] and RAS [25] in tissue culture and transgenic murine systems. In our current study, we also observed that transformed myoblasts expressing PAX3-FOXO1 are dependent on the fusion protein to overcome contact inhibition and induce cell proliferation in vitro and tumourigenesis in vivo. When PAX3-FOXO1 was depleted in these myoblasts in vitro or in vivo, the cells stopped proliferating and showed widespread differentiation and apoptosis. These changes resulted in shrinkage of the tumour to a non-palpable state within a few days. Our findings in this inducible myoblast system are concordant with previous studies of human ARMS cell lines in which knockdown of PAX3-FOXO1 resulted in reduced proliferation along with increased differentiation and cell death [12, 26, 27] , ultimately culminating in decreased tumour volume in vivo [28] .
Following regression, most tumours (>80%) in our model system recurred in the absence of doxycycline during the 90-day observation period. Although some of these recurrences resulted from acquisition of mechanisms to express PAX3-FOXO1 without doxycycline induction, many recurrences (60%) were associated with no detectable PAX3-FOXO1 protein expression. For these latter tumours, the initial oncogene-addicted tumour cells acquired mechanisms to bypass the addiction and overcome the detrimental effects of loss of fusion protein expression. Tumour recurrence in the absence of the initiating oncogene was previously described in several inducible tumour mouse models, such as Myc-inducible breast cancer [29] . We propose that such bypass mechanisms were acquired by one or more cells in the initial RMS tumour followed by gradual regrowth until a recurrent RMS tumour was detectable after a latent period of several weeks. The recurrent tumours showed heterogeneity in the length of this latent period, suggesting stochastic differences or differences in the underlying bypass mechanisms, regrowth rate, or number of aberrant cells in the initial tumour. As primary tumours do not form in the absence of doxycycline, even after extended observation, the appearance of these PAX3-FOXO1-independent tumours requires a prior period of PAX3-FOXO1 expression, indicating that these alternative oncogenic pathways may be initially activated or otherwise enabled by fusion protein expression. Although there may be multiple different molecular mechanisms underlying these recurrences, a common theme is a PAX3-FOXO1-independent block in myogenic differentiation. We propose that cells in which the transcriptional environment favours 636 PR Pandey et al PAX3-FOXO1-mediated inhibition of myogenic differentiation are selected during ARMS tumourigenesis. Furthermore, many recurrent tumours also possess a PAX3-FOXO1-independent mechanism for oncogenic transformation.
These inducible systems are valuable for modelling therapy targeted against oncoproteins. In these experimental systems, targeted therapy is simulated by withdrawal of the inducing agent, whereas, in clinical practice, the targeted therapy is addition of an agent that inactivates oncoprotein function. This targeted therapeutic effect can be bypassed following the development of primary or acquired resistance in a subset of tumour cells. Some resistance mechanisms involve genetic alterations, such as point mutation or amplification in the oncoprotein, whereas other resistance mechanisms involve acquisition of alternative oncogenic pathways in tumour cells [30, 31] . In the inducible experimental systems, recurrence is most likely caused by the latter group of mechanisms. In the doxycycline-inducible Myc breast cancer model, recurrence was associated with acquisition of activating point mutations in Ras family genes [32] .
In summary, our findings highlight the role of PAX3-FOXO1 in ARMS tumourigenesis and provide evidence for the evolution of fusion-positive RMS to a fusion protein-independent stage. The findings in this model animal system are consistent with our earlier molecular pathology studies of human ARMS tumours, which identified cases in which a fusion gene was detectable by in situ hybridization but the corresponding fusion transcript was not expressed [33] . Owing to the paucity of banked recurrent tumour specimens from ARMS patients, the frequency of fusion protein-independent recurrences with the current therapeutic regimens is not known. However, it should be acknowledged that there are currently no therapies targeted against the PAX3-FOXO1 fusion oncoprotein in RMS. We therefore hope that further investigation of this inducible model system will assist in the elucidation of the types of primary and acquired resistance that will be encountered as these targeted therapies are developed in the coming years. Figure S1 . Efficacy of doxycycline-inducible PAX3-FOXO1 expression system in human myoblasts Table S1 . Oligonucleotides used in qRT-PCR and CRISPR studies Table S2 . Primary tumour formation by engineered human myoblasts in the presence or absence of doxycycline during the 90-day observation period
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